BRKR — Bruker Corporation stock price, charts and financials

Latest market price

50.30

-14.01-21.79%

Overview Short InterestFilings

BRKRQT73Bruker Corporation·NASDAQ

Overview Short InterestFilings

50.30-21.79%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

BIO-0.55%$332.88 MASI+0.00%$179.95 GKOS-0.20%$170.53 GMED+0.06%$81.51 PODD-1.70%$166.82 ALGN+0.22%$173.27 LIVN+3.48%$85.33 PEN+0.37%$324.22

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	36.11%	Shs Outstand	152.23M	Perf Week	-20.04%

Market Cap	7.66B	Forward P/E	20.70	EPS next Y	2.43	Insider Trans	-0.02%	Shs Float	103.57M	Perf Month	-18.00%

Enterprise Value	9.19B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	14.13%	Perf Quarter	38.22%

Income	-12.00M	P/S	2.21	EPS this Y	983.59%	Inst Trans	-	Short Ratio	5.89	Perf Half Y	14.97%

Sales	3.46B	P/B	3.06	EPS next Y	14.60%	ROA	-0.19%	Short Interest	14.63M	Perf YTD	6.77%

Book/sh	16.44	P/C	57.57	EPS next 5Y	13.43%	ROE	-0.51%	52W High	65.30 -22.97%	Perf Year	32.40%

Cash/sh	0.87	P/FCF	186.47	EPS past 3/5Y	-	ROIC	-2.92%	52W Low	28.53 76.31%	Perf 3Y	-27.26%

Dividend Est.	0.20 (0.40%)	EV/EBITDA	30.35	Sales past 3/5Y	10.74% 11.57%	Gross Margin	45.56%	Volatility	6.27% 5.04%	Perf 5Y	-37.74%

Dividend TTM	0.20 (0.40%)	EV/Sales	2.66	EPS Y/Y TTM	-131.58%	Oper. Margin	5.89%	ATR (14)	3.78	Perf 10Y	110.46%

Dividend Ex-Date	Jun 22, 2026	Quick Ratio	0.72	Sales Y/Y TTM	2.73%	Profit Margin	-0.34%	RSI (14)	36.27	Recom	2.55

Dividend Gr. 3/5Y	0.00% 4.56%	Current Ratio	1.55	EPS Q/Q	-34.04%	SMA20	-16.04%	Beta	1.21	Target Price	52.17

Payout	-377.59%	Debt/Eq	0.81	Sales Q/Q	2.75%	SMA50	-13.38%	Rel Volume	3.42	Prev Close	64.31

Employees	11,085	LT Debt/Eq	0.79	Earnings	Nov 02	SMA200	9.38%	Avg Volume	2.59M	Price	50.30

IPO Date	Aug 04, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	35.14% 3.49%	Net Debt/EBITDA	5.08	Volume	8,861,493	Change	-21.79%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-29-26	Reiterated	Guggenheim	Buy	$58 → $70
Jun-24-26	Reiterated	UBS	Neutral	$53 → $60
May-08-26	Reiterated	Stifel Nicolaus	Hold	$40 → $45
May-07-26	Reiterated	Barclays	Overweight	$50 → $53
May-07-26	Reiterated	UBS	Neutral	$49 → $45
Feb-13-26	Reiterated	UBS	Neutral	$43 → $49
Feb-13-26	Reiterated	Goldman Sachs	Sell	$40 → $35
Feb-13-26	Reiterated	Barclays	Overweight	$55 → $50
Feb-12-26	Reiterated	Jefferies	Buy	$55 → $50
Jan-26-26	Reiterated	Guggenheim	Buy	$53 → $58

Latest News

Aug-04-26

Aug-04-2609:31PM

Bruker Corporation Q2 2026 Earnings Call SummaryYahoo

01:30PM

Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcriptseekingalpha.com

12:16PM

Dow, S&P 500 Climb to Fresh Record Highsschaeffersresearch.com

11:31AM

Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com

11:06AM

Bruker Q2 Earnings Call Highlightsmarketbeat.com

09:26AM

Bruker (BRKR) Q2 Earnings Beat Estimateszacks.com

08:00AM

Bruker Reports Second Quarter 2026 Financial Resultsgurufocus.com

Jul-31-26

Jul-31-2604:13AM

Dimensional Fund Advisors LP Grows Position in Bruker Corporation $BRKRdefenseworld.net

Jul-28-26

Jul-28-2607:47PM

Bruker Corp (BRKR) Stock Up 4.8% and Still Undervalued -- GF Score: 86/100gurufocus.com

03:15AM

Bank of New York Mellon Corp Decreases Stake in Bruker Corporation $BRKRdefenseworld.net

01:30AM

The London Company QTD Mid Cap Q2 2026 Contributors, Detractors And TradesSeekingAlpha

Jul-27-26

Jul-27-2604:45AM

First Trust Advisors LP Has $53.93 Million Holdings in Bruker Corporation $BRKRdefenseworld.net

04:13AM

California Public Employees Retirement System Sells 51,544 Shares of Bruker Corporation $BRKRdefenseworld.net

Jul-24-26

Jul-24-2604:01PM

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcastbusinesswire.com

Jul-23-26

Jul-23-2606:49PM

A Look at Bruker Corp (BRKR) After 4.0% Gain -- GF Value $62.85 vs Price $62.15gurufocus.com

Company

Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	3,458	3,437	3,366	2,965	2,531	2,418	1,988	2,073	1,896
Cost of Goods Sold Incl. D&A	1,883	1,859	1,717	1,451	1,225	1,208	1,048	1,077	996
Gross Profit	1,575	1,578	1,650	1,513	1,306	1,210	940	995	900
Selling, General and Administrative Excl. Other	963	947	894	729	607	562	478	505	445
Research and Development	399	395	377	295	236	221	198	188	173
Other Operating Expense	9	0	125	52	30	13	16	1	0
Operating Income	204	236	253	437	433	413	248	301	262
Interest Expense	59	60	48	16	16	14	14	16	13
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-131	-155	0	126	-2	-5	-8	-4	-5
Net Income Before Taxes	13	21	205	546	415	394	226	280	245
Income Taxes	24	29	91	118	116	113	64	82	64
Consolidated Net Income	-12	-9	113	427	297	277	158	197	180
Net Income From Continuing Operations	-9	-8	114	429	299	281	161	198	181
Net Income	-12	-9	113	427	297	277	158	197	180
EPS (Recurring)	-0.24	-0.15	0.76	2.92	2.00	1.83	1.03	1.27	1.15
EPS (Basic, Before Extraordinaries)	-0.24	-0.15	0.76	2.92	2.00	1.83	1.03	1.27	1.15
EPS (Diluted)	-0.24	-0.15	0.76	2.90	1.99	1.81	1.02	1.26	1.14
EBITDA	303	303	439	676	519	497	321	372	340
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	77.13	25.34	34.35	46.36	53.07	40.45	26.11
Price To Sales Ratio	2.21	2.08	2.59	3.62	4.02	5.24	4.17	3.81	2.45
Gross Margin	45.55	45.91	49.02	51.03	51.60	50.04	47.28	48.00	47.47
Operating Margin	5.90	6.87	7.52	14.74	17.11	17.08	12.47	14.52	13.82
Net Margin	-0.35	-0.26	3.36	14.40	11.73	11.46	7.95	9.50	9.49
Shares Outstanding	152	152	149	146	149	151	153	155	156
Market Capitalization	7,646	7,161	8,734	10,728	10,184	12,670	8,282	7,900	4,644
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Jul 15 '26	Option Exercise	22.19	2,000	44,380	130,443	Jul 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Jul 15 '26	Sale	60.25	2,000	120,500	128,443	Jul 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Jun 15 '26	Option Exercise	22.19	2,000	44,380	130,443	Jun 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Jun 15 '26	Sale	54.76	2,000	109,520	128,443	Jun 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	May 15 '26	Option Exercise	22.19	2,000	44,380	130,443	May 18
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	May 15 '26	Sale	43.90	2,000	87,800	128,443	May 18
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Apr 15 '26	Option Exercise	22.19	2,000	44,380	130,443	Apr 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Apr 15 '26	Sale	39.90	2,000	79,800	128,443	Apr 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Mar 13 '26	Option Exercise	22.19	2,000	44,380	130,443	Mar 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Mar 13 '26	Sale	35.44	2,000	70,880	128,443	Mar 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Feb 13 '26	Option Exercise	22.19	2,000	44,380	130,443	Feb 18
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Feb 13 '26	Sale	36.94	2,000	73,880	128,443	Feb 18
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Jan 15 '26	Option Exercise	22.19	2,000	44,380	130,443	Jan 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Jan 15 '26	Sale	49.20	2,000	98,400	128,443	Jan 16
Munch Mark	EXEC VP&PRES BRUKER NANO INC.	Jan 12 '26	Option Exercise	22.19	7,000	155,330	135,443	Jan 13

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.